Rajaie Cardiomyopathy and Myocarditis Registry
1 other identifier
observational
6,000
1 country
1
Brief Summary
The prevalence of patients with cardiomyopathies who referred to Rajaei Cardiovascular medical and research center is remarkable, and also the mission of this center is to achieve center of excellence in the field of cardiomyopathy. Rajaie Cardiomyopathy and myocarditis Registry study is an observational registry of consecutive patients with four cardiomyopathy subtypes: hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), and restrictive cardiomyopathy (RCM) as well as myocarditis designed to determine clinical characteristics, natural history, current therapeutic approaches, response to treatment and long-term outcomes of patients with cardiomyopathy and myocarditis and to address limitations in extant evidence to improve prognostication in cardiomyopathies and myocarditis. Prediction of mortality and response to different treatments in these patients using artificial intelligence is another aim of this registry
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2019
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 11, 2019
CompletedFirst Submitted
Initial submission to the registry
January 15, 2020
CompletedFirst Posted
Study publicly available on registry
March 11, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 11, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
November 11, 2025
CompletedMarch 11, 2020
March 1, 2020
1 year
January 15, 2020
March 7, 2020
Conditions
Outcome Measures
Primary Outcomes (5)
Admissions to hospital
Number of hospitalizations for cardiovascular reasons
1 year
Development of chronic heart failure
significant decrease in left ventricular ejection fraction
1 year
Prevalence of Stroke/Transient ischemic attack
At least 80% CT/MRI verification of the diagnosis of ischemic stroke/Transient ischemic attack, within the first week of stroke onset
1 year
Incidence of sudden death
unexpected death from a cardiovascular cause in a person with or without preexisting heart disease
1 year
Incidence of heart trasplantation
Cardiac transplantation in patients with end-stage HF who remain symptomatic despite optimal medical therapy
1 year
Secondary Outcomes (1)
response to current therapeutic approaches
1 year
Eligibility Criteria
Patients with documented cardiomyopathy/ myocarditis fulfilling standard diagnostic criteria based on the ESC guideline for cardiomyopathy/ myocarditis
You may qualify if:
- age greater than one year
- documented cardiomyopathy/ myocarditis fulfilling standard diagnostic criteria
- able to give informed consent or in the case of child consent from a parent
You may not qualify if:
- Patients who have not consent to participate in the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Behshid Ghadrdoost
Tehran, Iran
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Target Duration
- 12 Months
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 15, 2020
First Posted
March 11, 2020
Study Start
November 11, 2019
Primary Completion
November 11, 2020
Study Completion
November 11, 2025
Last Updated
March 11, 2020
Record last verified: 2020-03